{
  "docId": "019de072-e6c6-771e-b24a-5adaac3cef4b",
  "docSlug": "1c626f0801e0e9ad1e805f8e0140c291",
  "documentTitle": "Alkermes | Results Presentation Deck | 26 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 24,
  "pageCount": 26,
  "prevPage": 23,
  "nextPage": 25,
  "slideType": "other",
  "function": "present_solution",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide uses a grid-based layout to map clinical trials to strategic objectives.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de072-e6c6-771e-b24a-5adaac3cef4b/24",
  "deckHref": "/decks/019de072-e6c6-771e-b24a-5adaac3cef4b",
  "deckJsonHref": "/decks/019de072-e6c6-771e-b24a-5adaac3cef4b.json",
  "deckAnchorHref": "/decks/019de072-e6c6-771e-b24a-5adaac3cef4b#slide-24",
  "components": [
    {
      "bbox": {
        "h": 0.68,
        "w": 0.12,
        "x": 0.86,
        "y": 0.22
      },
      "kind": "list",
      "text": "Administration, Collaboration, and Region legends.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "af45581b-2a4d-461a-9a46-8a9a28ecb682",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.94,
        "x": 0.03,
        "y": 0.88
      },
      "kind": "subtitle",
      "text": "IV, Intravenous; SC, Subcutaneous; RP2D, Recommended phase 2 dose; ORR, Overall response rate; TME, Tumor microenvironment; MSD, A tradename of Merck & Co., Inc. Kenilworth, NJ, USA; GOG, Gynecologic Oncology Group, USA; ENGOT, European Network of Gynaecological Oncological Trial Groups",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f985bca0-918b-4057-8137-fe0ecb43bf21",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.68,
        "w": 0.83,
        "x": 0.03,
        "y": 0.22
      },
      "kind": "table",
      "text": "Grid of ARTISTRY trials (6, 7, 2, 3) and Next phase of development categorized by Potential Registration Supporting, Dose Options, and Potential Strategic Collaboration.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9958a18a-f84e-4d8e-a3cc-ed48a6251c4d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.12
      },
      "kind": "title",
      "text": "Nemvaleukin: Ongoing Studies to Support Broad Potential Use",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "377b69ad-61a7-4fc1-8d7d-9b9cf4c51463",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "2x2 matrix",
      "slug": "matrix-2x2",
      "agent": null,
      "layer": "slide",
      "matchId": "f300d237-0064-4668-ae4c-20a8fc851c78",
      "evidence": "table/data: Grid of ARTISTRY trials",
      "confidence": 0.5
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 26,
      "from": 21,
      "beatId": "4c209350-76ea-4ef7-8da0-7ce24752be33",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Impact & Next Steps",
      "beatSlug": "consultants-gambit-impact-next-steps",
      "evidence": "Slides 21-26 discuss the potential impact and next steps for Nemvaleukin Alfa.",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 26,
      "from": 21,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "c1538aa6-829a-4071-bbb6-a49e64a6fa94",
      "evidence": "Slides 21-26 discuss the potential for registration and next steps.",
      "position": 2,
      "objective": "What are the next steps for Nemvaleukin Alfa?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.7,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}